Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China

BACKGROUND: Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly understood, especially in a real‐world setting. METHODS: A multicenter observational study was conducted. Medical records of lung cancer patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuequan, Fang, Jian, Zhou, Chengzhi, Liu, Anwen, Wang, Yan, Meng, Qingwei, Ding, Cuimin, Ai, Bin, Gu, Yangchun, Yao, Yu, Sun, Hong, Guo, Hui, Zhang, Cuiying, Song, Xia, Li, Junling, Xu, Bei, Han, Zhiqiang, Song, Meijun, Tang, Tingyu, Chen, Peifeng, Lu, Hongmin, Shui, Yongjie, Lou, Guangyuan, Zhang, Dongming, Liu, Jia, Liu, Xiaoyan, Liu, Xiangning, Gao, Xiaoxing, Zhou, Qing, Chen, Minjiang, Zhao, Jing, Zhong, Wei, Xu, Yan, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807338/
https://www.ncbi.nlm.nih.gov/pubmed/34935288
http://dx.doi.org/10.1111/1759-7714.14274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807338/
https://www.ncbi.nlm.nih.gov/pubmed/34935288
http://dx.doi.org/10.1111/1759-7714.14274

Ejemplares similares